Squamous cell carcinoma of the lung medical therapy: Difference between revisions

	Squamous Cell Carcinoma of the Lung Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Squamous Cell Carcinoma of the Lung from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic study of choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Squamous cell carcinoma of the lung medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Squamous cell carcinoma of the lung medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Squamous cell carcinoma of the lung medical therapy
CDC on Squamous cell carcinoma of the lung medical therapy
Squamous cell carcinoma of the lung medical therapy in the news
Blogs on Squamous cell carcinoma of the lung medical therapy
Directions to Hospitals Treating Squamous cell carcinoma of the lung
Risk calculators and risk factors for Squamous cell carcinoma of the lung medical therapy

← Older edit Newer edit →

VisualWikitext

Revision as of 16:26, 7 March 2016

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shanshan Cen, M.D. [2] Maria Fernanda Villarreal, M.D. [3]

Overview

Medical Therapy

References

Template:WikiDoc Sources

@@ Line 4: / Line 4: @@
 ==Overview==
-Chemotherapy is indicated for non-small cell lung cancer stage (IB, II, and III) as adjuvant therapy. The predominant therapy for non-small cell lung cancer is surgical resection. Chemotherapy and chemoradiation may be required upon histological subtype of non-small cell lung cancer, location, size, and lymph node involvement. Commonly used chemotherapeutic agents, include: gemcitabine, paclitaxel, docetaxel, pemetrexed, etoposide or vinorelbine.
 ==Medical Therapy==
-*Initial medical therapy for patients with squamous cell carcinoma of the lung will depend on molecular testing (presence of genetic mutations)
-*Erlotinib is the first-line treatment for patients with squamous cell carcinoma of the lung whose cancer has spread to other parts of the body and that has certain types of epidermal growth factor receptor (EGFR) mutations.
-*Chemotherapy regimen by injection, includes:
-:*Paclitaxel (Abraxane)
-:*Cisplatin (Platinol-AQ)
-:*Gemcitabine (Gemzar)
-:*Carboplatin
-:*Etoposide (Etopophos)
-:*Docetaxel (Docefrez)
-:*Pemetrexed
-*Other chemotherapy regimen treatments, include:
-:*Afatinib
-:*Erlotinib (Tarceva)
-:*Gefitinib (Iressa)
-:*Crizotinib
-:*Bevacizumab by injection
-:*Vinorelbine by injection
-*Chemotherapy is indicated as adjuvant for stage IB, II, and III squamous cell carcinoma of the lung
-*Platinum-based chemotherapy (cisplatin, carboplatin, etoposide, irinotecan) are the mainstay of squamous cell carcinoma of the lung
-*Platinum-based chemotherapy  consists of four to six cycles
-==Complications of ==
-*Medical therapy complications for squamous cell carcinoma of the lung will depend on the chemotherapeutic agent.
-*Common chemotherapy complications, include:
-*Platinum-based chemotherapy
-*The main dose-limiting side effect of cancer treatment with platinum compounds, include:
-:*[[Neurotoxicity]]
-:*[[Peripheral neuropathy|Peripheral neuropathies]]
-*Other chemotherapeutic agent complications, include:
-:*[[Extravasation]]
-:*[[Cardiotoxicity]]

Squamous cell carcinoma of the lung medical therapy: Difference between revisions

Revision as of 16:26, 7 March 2016

Overview

Medical Therapy

References

Navigation menu

Search